• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU
Click for more information
1.06% $18.65

NEUREN PHARMACEUTICALS LIMITED - Corporate Spotlight

Market Cap $2.381B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

(20min delay)
Last
$18.65 		Change
-0.200(1.06%) 		Mkt cap ! $2.381B
Open High Low Value Volume
$18.85 $18.92 $18.35 $10.53M 566.6K

Buyers (Bids)

No. Vol. Price($)
1 45 $18.64
 

Sellers (Offers)

Price($) Vol. No.
$18.73 1500 1
View Market Depth
Last trade - 16.10pm 26/04/2024 (20 minute delay) ?
Last
$18.73 		  Change
-0.200 ( 0.73 %)
Open High Low Volume
$18.89 $18.89 $18.36 91292
Last updated 15.59pm 26/04/2024 ?
NEU (ASX) Chart

Top Stories

Are there gains to be made with the grocery giants?

There is a growing storm of controversy around Coles (ASX:COL) and Woolworths (ASX:WOW) as they face intense scrutiny over price hikes and supplier pressures in a Senate inquiry. This raises an interesting question as to whether investors should cut ties with these corporate giants or wheth...
Regal copper grades at Gascoyne play see shares jump 33% for Augustus Augustus Minerals is reporting high grade copper rock chip results at Ti-Tree in WA based on recent fieldwork.
Recce Pharmaceuticals up 6% on new antibiotic production milestone Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.
Raiden’s jump into lithium territory in WA’s Pilbara echoes earlier journey by Azure In its bid to define a noteworthy lithium deposit in WA’s Pilbara region, Raiden Resources is following in the footsteps of another explorer.
BHP confirms £31.1B takeover bid for Anglo American BHP HAS confirmed its offer to takeover fellow mining giant Anglo American plc, following press speculation of a potential deal.which had unsettled shareholder groups and financial firms in London, and provoked criticism from a South African government minister.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.